CEO Patrik Dahlen purchases Immunovia shares
LUND, SWEDEN - Immunovia AB (publ) (“Immunovia”) announces today that Patrik Dahlen, CEO of Immunovia, has purchased 6,860 shares for approximately SEK 675,000 over the stock exchange. His total holding now amounts to 51,860 shares in Immunovia. For more information, please contact:Patrik Dahlen, CEO ImmunoviaEmail: patrik.dahlen@immunovia.comTel: +46 73 376 76 64 About ImmunoviaImmunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test